Matches in SemOpenAlex for { <https://semopenalex.org/work/W2774548242> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2774548242 endingPage "A48" @default.
- W2774548242 startingPage "A47.4" @default.
- W2774548242 abstract "Background Evidence suggests cladribine is an effective, safe and convenient disease modifying therapy (DMT) for people with multiple sclerosis (pwMS). Objective To report our clinical experience using cladribine in pwMS using a dosing scheme adapted to individual total lymphocyte count (TLC) thereby addressing a key safety concern raised in the rejection of oral cladribine by the European Medicines Agency in 2011. Methods Subcutaneous cladribine 10 mg/day was administered on up to seven days in five weeks to pwMS who had clinical and/or MRI disease activity. The number of injections was adjusted to individual TLC to avoid depletion below 0.5 × 10* 9/L (WHO Grade 3 or 4). Efficacy and safety were assessed. Results Forty-nine pwMS (31 women and 18 men, aged 44 years (SD=9 )) were followed up for a mean of 6 months after their first cladribine injection. Median EDSS at baseline was 5 (1–8, n=46). No serious treatment-related adverse event was observed, and neither any clinical disease activity. TLC dropped to between 0.5 and 1 × 10* 9/L while other white cells remained within normal range. Conclusion Cladribine was well tolerated and led to controlled TLC depletion leaving other cell lines largely unaffected. So far no new disease activity has been detected. Follow-up continues." @default.
- W2774548242 created "2017-12-22" @default.
- W2774548242 creator A5002975609 @default.
- W2774548242 creator A5008008791 @default.
- W2774548242 creator A5013091160 @default.
- W2774548242 creator A5015754502 @default.
- W2774548242 creator A5016912802 @default.
- W2774548242 creator A5018748002 @default.
- W2774548242 creator A5044046113 @default.
- W2774548242 creator A5050732832 @default.
- W2774548242 creator A5057445606 @default.
- W2774548242 creator A5066093073 @default.
- W2774548242 date "2017-12-01" @default.
- W2774548242 modified "2023-10-16" @default.
- W2774548242 title "PO134 Personalised dosing of cladribine to treat multiple sclerosis" @default.
- W2774548242 doi "https://doi.org/10.1136/jnnp-2017-abn.164" @default.
- W2774548242 hasPublicationYear "2017" @default.
- W2774548242 type Work @default.
- W2774548242 sameAs 2774548242 @default.
- W2774548242 citedByCount "1" @default.
- W2774548242 countsByYear W27745482422018 @default.
- W2774548242 crossrefType "journal-article" @default.
- W2774548242 hasAuthorship W2774548242A5002975609 @default.
- W2774548242 hasAuthorship W2774548242A5008008791 @default.
- W2774548242 hasAuthorship W2774548242A5013091160 @default.
- W2774548242 hasAuthorship W2774548242A5015754502 @default.
- W2774548242 hasAuthorship W2774548242A5016912802 @default.
- W2774548242 hasAuthorship W2774548242A5018748002 @default.
- W2774548242 hasAuthorship W2774548242A5044046113 @default.
- W2774548242 hasAuthorship W2774548242A5050732832 @default.
- W2774548242 hasAuthorship W2774548242A5057445606 @default.
- W2774548242 hasAuthorship W2774548242A5066093073 @default.
- W2774548242 hasConcept C126322002 @default.
- W2774548242 hasConcept C177713679 @default.
- W2774548242 hasConcept C19527891 @default.
- W2774548242 hasConcept C203014093 @default.
- W2774548242 hasConcept C2777288759 @default.
- W2774548242 hasConcept C2779200787 @default.
- W2774548242 hasConcept C2780640218 @default.
- W2774548242 hasConcept C71924100 @default.
- W2774548242 hasConcept C98274493 @default.
- W2774548242 hasConceptScore W2774548242C126322002 @default.
- W2774548242 hasConceptScore W2774548242C177713679 @default.
- W2774548242 hasConceptScore W2774548242C19527891 @default.
- W2774548242 hasConceptScore W2774548242C203014093 @default.
- W2774548242 hasConceptScore W2774548242C2777288759 @default.
- W2774548242 hasConceptScore W2774548242C2779200787 @default.
- W2774548242 hasConceptScore W2774548242C2780640218 @default.
- W2774548242 hasConceptScore W2774548242C71924100 @default.
- W2774548242 hasConceptScore W2774548242C98274493 @default.
- W2774548242 hasIssue "Suppl 1" @default.
- W2774548242 hasLocation W27745482421 @default.
- W2774548242 hasOpenAccess W2774548242 @default.
- W2774548242 hasPrimaryLocation W27745482421 @default.
- W2774548242 hasRelatedWork W1955491518 @default.
- W2774548242 hasRelatedWork W2010294647 @default.
- W2774548242 hasRelatedWork W2088439566 @default.
- W2774548242 hasRelatedWork W2481644619 @default.
- W2774548242 hasRelatedWork W2904884305 @default.
- W2774548242 hasRelatedWork W3097455770 @default.
- W2774548242 hasRelatedWork W3216401883 @default.
- W2774548242 hasRelatedWork W4205332320 @default.
- W2774548242 hasRelatedWork W4280585883 @default.
- W2774548242 hasRelatedWork W4306923031 @default.
- W2774548242 hasVolume "88" @default.
- W2774548242 isParatext "false" @default.
- W2774548242 isRetracted "false" @default.
- W2774548242 magId "2774548242" @default.
- W2774548242 workType "article" @default.